Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain

Annals of Pharmacotherapy

Volumn 44, Issue 4, 2010, Pages 668-679

  Ellinger, Lara K ^a   Ipema, Heather J ^a   Stachnik, Joan M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Atypical antipsychotic; Metformin; Obesity; Schizophrenia; Topiramate; Weight gain

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; ILOPERIDONE; METFORMIN; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; ZIPRASIDONE;

ANOREXIA; BLOATING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONCENTRATION LOSS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FATIGUE; FLATULENCE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MEDLINE; OBESITY; PARESTHESIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; ANTIPSYCHOTIC AGENTS; FRUCTOSE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT GAIN;

EID: 77950612221     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M550     Document Type: Review

References (89)

1. Crimson ML, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw-Hill, 2008:1099-1139
2. Endow-Eyer RA, Mitchell MM, Lacro JP. Schizophrenia. In: Koda-Kimble M, Young LY, Alldredge BK, et al., eds. Applied therapeutics: the clinical use of drugs, 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2009:78-1, 78-134
3. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
4. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696 (Pubitemid 29517559)
5. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-526 DOI 10.1038/sj.npp.1300027
6. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35. DOI 10.1038/sj.mp.4002066 (Pubitemid 350275185)
7. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-160 (Pubitemid 34686785)
8. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
9. Product information. Abilify (aripiprazole). Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd., July 2009.
10. Product information. Saphris (asenapine). Kenilworth, NJ: Schering-Plough Corporation, August 2009.
11. Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994;55(suppl B):157-160 (Pubitemid 24353043)
12. Product information. Fanapt (iloperidone). Rockville, MD: Vanda Pharmaceuticals Inc., July 2009.
13. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223 DOI 10.1056/NEJMoa051688 (Pubitemid 41345943)
14. Product information. Invega (paliperidone). Mountain View, CA: Alza Corporation, July 2009.
15. Hester EK, Thrower MR. Current options in the management of olanzapine-associated weight gain. Ann Pharmacother 2005;39:302-310 Doi 10.1345/aph.1D423 (Pubitemid 40165221)
16. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of adults and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-685 (Pubitemid 43848299)
17. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773 DOI 10.1001/jama.2009.1549
18. Shin L, Bregman H, Frazier J, Noyes N. An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. Harv Rev Psychiatry 2008;16:69-79. DOI 10.1080/10673220802073915 (Pubitemid 351549825)
19. McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008;162:929-935 DOI 10.1001/archpedi.162.10.929
20. Schneiderhan ME, Marvin R. Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain? Am J Ther 2007;14:581-584 DOI 10.1097/MJT.0b013e31813e65b7 (Pubitemid 350307695)
21. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005;162: 1744-1746 DOI 10.1176/appi.ajp.162.9.1744 (Pubitemid 41318248)
22. Deberdt W, Winokur A, Cavazzoni PA, et al. Amantadine for weight gain associated with olanzapine treatment. Eur Neuropsychopharmacol 2005;15:13-21. DOI 10.1016/j.euroneuro.2004.03.005 (Pubitemid 39574395)
23. Bahk WM, Lee KU, Chae JH, Pae CU, Jun T, Kim KS. Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry Clin Neurosci 2004;58:163-167 (Pubitemid 38470538)
24. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001;11:181-182 (Pubitemid 32335561)
25. Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight gain in children and adolescents: case series. J Child Adolesc Psychopharmacol 2002;12:249-257 DOI 10.1089/104454602760386941
26. Poyurovsky M, Pashinian A, Levi A, Weizman R, Weizman A. The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol 2005;20:101-103 (Pubitemid 40354400)
27. Gadde KM, Zhang W, Foust MS. Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. J Clin Psychopharmacol 2006;26:409-413 DOI 10.1097/01.jcp.0000227354.54074.5d (Pubitemid 44187645)
28. Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. The effect of famotidine addition on olanzapine-induced weight gain in firstepisode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004;14:332-336 DOI 10.1016/j.euroneuro.2003.10.004 (Pubitemid 38649091)
29. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology 2003;28:527-529 DOI 10.1038/sj.npp.1300089
30. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebocontrolled study of fluoxetine addition. Am J Psychiatry 2002;159:1058-1060 (Pubitemid 34586958)
31. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxam-ine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004;65:766-771
32. Schaefer M, Leopold K, Hinzpeter A, Heinz A, Krebs M. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007;40:149-151 DOI 10.1055/s-2007-984391 (Pubitemid 47434873)
33. Carrizo E, Fernandez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009;113:19-26. DOI 10.1016/j.schres.2009.05.007
34. Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, doubleblind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008;29:1130-1134
35. Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008;159:250-253 DOI 10.1016/j.psychres.2008.01.011
36. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299:185-193 DOI 10.1001/jama.2007.56-b
37. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93:99-108. DOI 10.1016/j.schres.2007.03.029 (Pubitemid 46839067)
38. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165:352-358 DOI 10.1176/appi.ajp.2007.07010079 (Pubitemid 351704491)
39. Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51:192-196
40. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163:2072-2079 DOI 10.1176/appi.ajp.163.12.2072 (Pubitemid 46114226)
41. Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:925-931 DOI 10.1016/j.pnpbp.2007. 11.013 (Pubitemid 351609224)
42. Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001;62:653-655 (Pubitemid 32848172)
43. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA. Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 2009;19:275-279 DOI 10.1089/cap.2008.094
44. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159: 655-657
45. Ozenoglu A, Ugurlu S, Balci H, Eker E. Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report. Intern Med 2007;46:1213-1218 (Pubitemid 47354440)
46. Roerig JL, Steffen KJ, Mitchell JE, Crosby RD, Gosnell BA. An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects. Biol Psychiatry 2009;65:607-613 DOI 10.1016/j.biopsych.2008.10.037
47. Henderson DC, Louie PM, Koul P, Namey L, Daley TB, Nguyen DD. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 2005;17:95-97 (Pubitemid 40967132)
48. Assuncao SS, Ruschel SI, Rosa Lde C, et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev Bras Psiquiatr 2006;28:270-276
49. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003;18:457-461 Doi 10.1002/hup.514 (Pubitemid 37038342)
50. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 2004;19:37-40. DOI 10.1002/hup.477 (Pubitemid 38159274)
51. Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003;13:81-85 (Pubitemid 36321748)
52. Pae CU, Kim JJ, Lee KU, et al. Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study. Hum Psychopharmacol 2003;18:453-456 DOI 10.1002/hup.507 (Pubitemid 37038341)
53. Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000;48:167-168 (Pubitemid 30618806)
54. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:706-711 (Pubitemid 351838679)
55. Carpenter LL, Schecter JM, Sinischalc J, Leon Z, Price LH. A case series describing orlistat use in patients on psychotropic medications. Med Health R I 2004;87:375-377
56. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000;20:716-717
57. Pavlovic ZM. Orlistat in the treatment of clozapine-induced hyperglycemia and weight gain. Eur Psychiatry 2005;20:520. DOI 10.1016/j.eurpsy.2005.07.005 (Pubitemid 41681562)
58. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 2002;63:345-348
59. Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boullosa O. Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration. Vertex 2003;14:85-96. DOI 10.1267/science.040579197
60. Poyurovsky M, Fuchs C, Pashinian A, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl) 2007;192:441-448 DOI 10.1007/s00213-007-0731-1 (Pubitemid 46701583)
61. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003;160:297-302. (Pubitemid 41110455)
62. Baptista T, Rangel N, El Fakih Y, et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 2009;42:14-19 DOI 10.1055/s-0028-1085438
63. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007;115:101-105 DOI 10.1111/j.1600-0447.2006.00855.x (Pubitemid 46114870)
64. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162:954-962 DOI 10.1176/appi.ajp.162.5.954 (Pubitemid 40676209)
65. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007;9:426-434 DOI 10.1111/j.1399-5618.2007.00488.x (Pubitemid 46865373)
66. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009;23:157-162 DOI 10.1177/0269881108089816
67. Nickel MK, Nickel C, Muehlbacher M, et al. Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25:211-217 (Pubitemid 40685783)
68. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28:169-175 (Pubitemid 41134243)
69. Egger C, Muehlbacher M, Schatz M, Nickel M. Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol 2007;27:475-478 DOI 10.1097/jcp.0b013e31814b98e5 (Pubitemid 47415045)
70. Tramontina S, Zeni CP, Pheula G, Rohde LA. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psychopharmacol 2007;17:129-134 DOI 10.1089/cap.2006.0024 (Pubitemid 46452089)
71. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82:115-117 DOI 10.1016/j.schres.2005.10.001 (Pubitemid 43202654)
72. Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-232 DOI 10.1016/j.braindev.2004.06.006 (Pubitemid 40312035)
73. Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004;24:374-378 (Pubitemid 38944134)
74. Khazaal Y, Chatton A, Rusca M, Preisig M, Zullino D. Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review. Gen Hosp Psychiatry 2007;29:446-449 DOI 10.1016/j.genhosppsych.2007.05. 001 (Pubitemid 47410300)
75. Levy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 2007;14:e234-9. (Pubitemid 47324700)
76. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005;59:613-615 DOI 10.1111/j.1440-1819.2005.01424.x (Pubitemid 41765763)
77. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002;63:1045. (Pubitemid 35388066)
78. Lessig MC, Shapira NA, Murphy TK. Topiramate for reversing atypical antipsychotic weight gain. J Am Acad Child Adolesc Psychiatry 2001; 40:1364. (Pubitemid 34250952)
79. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45:198. (Pubitemid 30238116)
80. Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw-Hill, 2008:1205-1241
81. Metformin. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, last modified 2009 Oct 30 (accessed 2009 Nov 22).
82. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009;37:2191-2196 DOI 10.1097/CCM.0b013e3181a02490
83. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-494 (Pubitemid 32198418)
84. Topiramate. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, last modified 2009 Oct 20 (accessed 2009 Nov 22).
85. Rogers SJ, Cavazs JE. Epilepsy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 7th ed. New York, NY: McGraw-Hill, 2008:927-951
86. Desilets AR, Dhakal-Karki S, Dunican KC. Role of metformin for weight management in patients without type 2 diabetes. Ann Pharmacother 2008;42:817-826 DOI 10.1345/aph.1K656 (Pubitemid 351778088)
87. Product information. Topamax (topiramate). Titusville, NJ: Ortho-McNeil Neurologics, April 2008.
88. Bushe CJ, Bradley AJ, Doshi S, Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009;63:1743-1761 DOI 10.1111/j.1742-1241. 2009.02224.x
89. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;(1):CD005148. DOI 10.1002/14651858.CD005148.pub2 (Pubitemid 351820500)